Edition:
United States

BTG PLC (BTG.L)

BTG.L on London Stock Exchange

538.50GBp
22 Jun 2018
Change (% chg)

6.50 (+1.22%)
Prev Close
532.00
Open
530.00
Day's High
543.50
Day's Low
521.00
Volume
769,793
Avg. Vol
832,115
52-wk High
784.00
52-wk Low
482.40

Chart for

About

BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and... (more)

Overall

Beta: 0.29
Market Cap(Mil.): £2,081.27
Shares Outstanding(Mil.): 386.49
Dividend: --
Yield (%): --

Financials

  BTG.L Industry Sector
P/E (TTM): -- 29.56 34.14
EPS (TTM): -0.06 -- --
ROI: -2.22 13.56 13.10
ROE: -2.24 15.35 15.09

BTG owes Wellstat $55.8 mln in drug contract dispute: Delaware top court

The Delaware Supreme Court has upheld a decision requiring British pharmaceutical company BTG Plc to pay $55.8 million plus interest to Wellstat Therapeutics Corp for failing to properly market the latter's chemotherapy overexposure antidote.

Jun 12 2018

U.S. court invalidates J&J cancer drug patent, hitting UK's BTG

NEW YORK A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .

Jan 18 2018

UPDATE 1-U.S. court invalidates J&J cancer drug patent, hitting UK's BTG

NEW YORK, Jan 18 A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc.

Jan 18 2018

Earnings vs. Estimates